The Insulin Sensitivity Mcauley Index (MCAi) is Associated with 40-year Cancer Mortality in a Cohort of Men and Women Free of Diabetes at Baseline

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Aug 3

PMID 35921366

Authors

Yonatan Moshkovits

David Rott

Angela Chetrit

Rachel Dankner

Affiliations

Soon will be listed here.

Abstract

Background: The association between insulin resistance and cancer-mortality is not fully explored. We investigated the association between several insulin sensitivity indices (ISIs) and cancer-mortality over 3.5 decades in a cohort of adult men and women. We hypothesized that higher insulin resistance will be associated with greater cancer-mortality risk.

Methods: A cohort of 1,612 men and women free of diabetes during baseline were followed since 1979 through 2016 according to level of insulin resistance (IR) for cause specific mortality, as part of the Israel study on Glucose Intolerance, Obesity and Hypertension (GOH). IR was defined according to the Mcauley index (MCAi), calculated by fasting insulin and triglycerides, the Homeostatic Model Assessment (HOMA), the Matsuda Insulin Sensitivity Index (MISI), and the Quantitative Insulin Sensitivity Check Index (QUICKI), calculated by plasma glucose and insulin.

Results: Mean age at baseline was 51.5 ± 8.0 years, 804 (49.9%) were males and 871 (54.0%) had prediabetes. Mean follow-up was 36.7±0.2 years and 47,191 person years were accrued. Cox proportional hazard model and competing risks analysis adjusted for age, sex, country of origin, BMI, blood pressure, total cholesterol, smoking and glycemic status, revealed an increased risk for cancer-mortality, HR = 1.5 (95% CI: 1.1-2.0, p = 0.005) for the MCAi Q1 compared with Q2-4. No statistically significant associations were observed between the other ISIs and cancer-mortality.

Conclusion: The MCAi was independently associated with an increased risk for cancer-mortality in adult men and women free of diabetes and should be further studied as an early biomarker for cancer risk.

Citing Articles

Association of body mass index and blood pressure variability with 10-year mortality and renal disease progression in type 2 diabetes.

Fava S, Reiff S Acta Diabetol. 2024; 61(6):747-754.

PMID: 38438789 PMC: 11101579. DOI: 10.1007/s00592-024-02250-z.

References

Goldman A, Hod H, Chetrit A, Dankner R . Incidental abnormal ECG findings and long-term cardiovascular morbidity and all-cause mortality: A population based prospective study. Int J Cardiol. 2019; 295:36-41. DOI: 10.1016/j.ijcard.2019.08.015. View

Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N . Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364(9):829-841. PMC: 4109980. DOI: 10.1056/NEJMoa1008862. View

Li X, Tang H, Wang J, Xie X, Liu P, Kong Y . The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast. 2016; 32:1-6. DOI: 10.1016/j.breast.2016.11.024. View

Ausk K, Boyko E, Ioannou G . Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care. 2010; 33(6):1179-85. PMC: 2875420. DOI: 10.2337/dc09-2110. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R . Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009; 6(12):e1000201. PMC: 2791167. DOI: 10.1371/journal.pmed.1000201. View

Hsing A, Gao Y, Chua Jr S, Deng J, Stanczyk F . Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003; 95(1):67-71. DOI: 10.1093/jnci/95.1.67. View

Dankner R, Shanik M, Keinan-Boker L, Cohen C, Chetrit A . Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care. 2012; 35(7):1538-43. PMC: 3379575. DOI: 10.2337/dc11-1513. View

Emaus A, Veierod M, Tretli S, Finstad S, Selmer R, Furberg A . Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat. 2009; 121(3):651-60. DOI: 10.1007/s10549-009-0603-y. View

10.

Kerr J, Anderson C, Lippman S . Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. Lancet Oncol. 2017; 18(8):e457-e471. PMC: 10441558. DOI: 10.1016/S1470-2045(17)30411-4. View

11.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. DOI: 10.1007/BF00280883. View

12.

Dankner R, Boffetta P, Balicer R, Boker L, Sadeh M, Berlin A . Time-Dependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults. Am J Epidemiol. 2016; 183(12):1098-106. DOI: 10.1093/aje/kwv290. View

13.

Moshkovits Y, Rott D, Chetrit A, Dankner R . The association between insulin sensitivity indices, ECG findings and mortality: a 40-year cohort study. Cardiovasc Diabetol. 2021; 20(1):97. PMC: 8103608. DOI: 10.1186/s12933-021-01284-9. View

14.

Johnson J, Bowker S . Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2010; 54(1):25-31. DOI: 10.1007/s00125-010-1933-3. View

15.

Tsuchida K, Oike T, Ohtsuka T, Ide M, Takakusagi Y, Noda S . Solitary cardiac metastasis of uterine cervical cancer with antemortem diagnosis: A case report and literature review. Oncol Lett. 2016; 11(5):3337-3341. PMC: 4841013. DOI: 10.3892/ol.2016.4415. View

16.

Kaye J, Meier C, Walker A, Jick H . Statin use, hyperlipidaemia, and the risk of breast cancer. Br J Cancer. 2002; 86(9):1436-9. PMC: 2375376. DOI: 10.1038/sj.bjc.6600267. View

17.

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care. 2006; 29(8):1990-1. DOI: 10.2337/dc06-0997. View

18.

Esposito K, Ciardiello F, Giugliano D . Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine. 2014; 46(1):39-42. DOI: 10.1007/s12020-013-0151-4. View

19.

Placzkowska S, Pawlik-Sobecka L, Kokot I, Piwowar A . Indirect insulin resistance detection: Current clinical trends and laboratory limitations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019; 163(3):187-199. DOI: 10.5507/bp.2019.021. View

20.

Wulaningsih W, Vahdaninia M, Rowley M, Holmberg L, Garmo H, Malmstrom H . Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer. 2015; 15:913. PMC: 4650114. DOI: 10.1186/s12885-015-1928-z. View